With Stars progress on track and a disciplined 2027 bid strategy, Humana is positioning for the margin recovery it has promised — and the tape is listening.
HUM · Earnings Call · 2026-07-29
Stars: The Long-Delayed Payoff
The most consequential change this quarter is not a number but a posture. For the first time in a year, Humana management shared tangible evidence that its Stars turnaround is working. Stars revenue per member per month — the metric Jim Rechtin now wants investors to watch — is the lens through which they want the market to evaluate the company. The prepared remarks revealed that across a selected set of HEDIS and Patient Safety metrics, "our rate of improvement outpaced and in many places, meaningfully outpaced the historical CAGR across 11 of the 12 measures." That's a concrete claim, and it explains why the company is reiterating its BY28 top-quartile target.
Our outlook on bonus year '28 or BY '28 Stars remains unchanged. We continue to be confident we are on the right track to return to top quartile Stars results in BY '28.
In the Q&A, Rechtin acknowledged the threshold uncertainty but argued that the operational progress gives them "a good place that even if we have some surprises on thresholds... we will be able to navigate to a place that is consistent with our commitment." “We have looked at thresholds a number of different ways. And we do believe that this operational progress puts us in a good place...” — James Rechtin, President and Chief Executive Officer · 2026-07-29 This is a meaningfully different tone from the hedge of previous quarters.
Margins: Bids and Plan Exits
The second major theme is the 2027 bid strategy. After a year of stable benefits, management is now willing to make targeted plan exits to accelerate margin progression. Celeste Mellet was explicit: "For 2027, we anticipate these plan exits will impact approximately 600,000 members, though we will work to recapture a significant portion of that volume as we did in 2025." “...” — Celeste Mellet, Chief Financial Officer · 2026-07-29 This is a clear shift from the previous year's approach. plan exit is a new high-momentum keyword, and management frames it as a deliberate portfolio decision to protect higher-value plans with greater value based care penetration. The emphasis on site of service and site of care initiatives ties directly into the margin bridge.The mix of benefit adjustments, clinical excellence, and operating efficiency is the same playbook but with a harder edge. In the prior quarter, Jim had noted that "the gap between funding and medical cost trend is larger going into this bid season than it was a year ago." “...” — James Rechtin · 2026-04-29 Now they're acting on it.
Capital and Operational Efficiency
Beyond Stars and bids, the company is deploying new capital tools. Celeste highlighted the establishment of $1.5 billion in contingent capital facilities using P-Caps, a first in the health payer space. This is part of a broader balance sheet efficiency push that also includes the divestiture of Gentiva and the acquisition of MaxHealth. asset divestitures have been a recurring theme, but the pace has accelerated.Operationally, the transformation office is yielding results. Jim pointed to "hundreds of millions of dollars in value so far in 2026." operational progress is no longer aspirational; it's quantifiable.
What Changed and Why It Matters
The market has rewarded this report violently: the stock is up ~97% over the last 90 days, with most of that move occurring in the last seven weeks. The tape is voting that the Stars recovery is real. Fundamentally, the company is growing revenue but still compressing margins: operating income fell 13% year-over-year even as total revenue grew 23%. The 2027 bid strategy and Stars recovery are the two levers that could flip that equation.The credibility of the story hinges on execution, and for the first time in a long time, Humana is showing evidence rather than promises. The December investor update will be the next checkpoint.